Neurocrine Biosciences (NBIX) Revenue (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Revenue of $959.0 million for Q2 2026, up 39.49% year-over-year from $687.5 million in Q2 2025, and up 17.74% on a QoQ basis from $814.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Revenue (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Revenue for 16 years, with the latest figure at $959.0 million in Q2 2026.
- Revenue for Q2 2026 came in at $959.0 million, up 39.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.4 billion (up 34.42% YoY), and the FY2025 annual result was $2.9 billion, up 21.45% from the prior year.
- Revenue climbed to $959.0 million in Q2 2026, from $814.5 million in the prior quarter.
- Over five years, Revenue peaked at $959.0 million in Q2 2026 and troughed at $20.0 million in Q2 2022.
- A 5-year average of $555.9 million and a median of $543.9 million in 2024 frame the typical range for Revenue.
- The widest annual swing landed in 2022, when Revenue plunged 93.08%; it then jumped 2163.5% in 2023.
- A 5-year view of Revenue shows it stood at $412.0 million in 2022, then advanced by 25.05% to $515.2 million in 2023, then advanced by 21.84% to $627.7 million in 2024, then climbed by 28.33% to $805.5 million in 2025, then increased by 19.06% to $959.0 million in 2026.
- Per Business Quant data, the three most recent Revenue figures were $959.0 million in Q2 2026, $814.5 million in Q1 2026, and $805.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 106.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 1.37 Bn |
| 10 | HUTCHMED (China) | 10.92 Bn | 9.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 959.00 Mn |
| Mar 31, 2026 | 814.50 Mn |
| Dec 31, 2025 | 805.50 Mn |
| Sep 30, 2025 | 794.90 Mn |
| Jun 30, 2025 | 687.50 Mn |
| Mar 31, 2025 | 572.60 Mn |
| Dec 31, 2024 | 627.70 Mn |
| Sep 30, 2024 | 622.10 Mn |
| Jun 30, 2024 | 590.20 Mn |
| Mar 31, 2024 | 515.30 Mn |
| Dec 31, 2023 | 515.20 Mn |
| Sep 30, 2023 | 498.80 Mn |
| Jun 30, 2023 | 452.70 Mn |
| Mar 31, 2023 | 420.40 Mn |
| Dec 31, 2022 | 412.00 Mn |
| Sep 30, 2022 | 387.90 Mn |
| Jun 30, 2022 | 20.00 Mn |
| Mar 31, 2022 | 310.60 Mn |
| Dec 31, 2021 | 312.00 Mn |
| Sep 30, 2021 | 296.00 Mn |